Hello Subs,
Last week, RNTX raised $50M to push LTI-03 forward in a Phase 2 study called RENEW. I find the drug mechanistically interesting, with net directionally positive Phase 1b and preclinical data. The Phase 2 RENEW study carries significant risk, with the odds of success at this stage likely still below 50%. But the $50M financing is signaling something, and I think there are a few ways investors can win here.
My podcast covers the financing, the preclinical data, the Phase 1b data, the market opportunity, and why I think RNTX is attractive here at $1.03/sh - just 3 pennies above where the $50M financing took place last week.
Cheers,
JNap
